Newswise — LA JOLLA, CA – February 4, 2015 – Scientists at The Scripps Research Institute (TSRI) have found diverse genomic changes in single neurons from the brains of Alzheimer’s patients, pointing to an unexpected factor that may underpin the most common form of the disease.
A new study, published February 4, 2015 in the online journal eLife, shows that Alzheimer’s brains commonly have many neurons with significantly more DNA and genomic copies of the Alzheimer’s-linked gene, APP, than normal brains.
“Our findings open a new window into the normal and diseased brain by providing the first evidence that DNA variation in individual neurons could be related to brain function and Alzheimer’s disease,” said Jerold Chun, professor at TSRI and its Dorris Neuroscience Center and senior author of the new study.
A Devastating Disease of Unknown Cause
Alzheimer’s disease is an irreversible brain disease that tends to strike older people. It is progressive—impairing memory, destroying motor skills and eventually causing death. The U.S. Centers for Disease Control and Prevention estimates 5.3 million Americans currently have Alzheimer’s disease, and that number is expected to double by 2050 as the population ages.
Scientists still do not know what triggers the majority of Alzheimer’s cases, making it difficult to develop a treatment. Some genes have been identified in families, however 95 percent of cases are “sporadic,” with no link to a gene or family history of Alzheimer’s.
Researchers have long known about disease-related protein accumulations (called amyloid plaques) in the brains of Alzheimer’s patients. They’ve also known that chromosome 21 plays a role in the disease, due to Alzheimer’s-like symptoms in people with Down syndrome (with three copies of chromosome 21). This chromosome contains the APP gene, which can lead to production of the primary component of the damaging amyloid plaques.
Chun and his laboratory group have had a longstanding interest in genomic variation among brain cells, which produces “genomic mosaicism.” In 2001, Chun was the first to report that the brain contains many distinct genomes within its cells—much like the colorful tiles in an artist’s mosaic.
“When we started, genomic mosaicism in the brain was not recognized,” said Chun. “But it turns out there is a remarkable range of genomic changes encompassed by DNA content variation in single brain cells.”
The Alzheimer’s Brain as a Mosaic
In the new study, Chun and his colleagues first set out to analyze the overall DNA content in cells, comparing 32 post-mortem Alzheimer’s brains and 21 post-mortem non-diseased brains.
Remarkably, the researchers found that more than 90 percent of sporadic Alzheimer’s disease brains displayed highly significant DNA increases of hundreds of millions more DNA base-pairs, compared with control samples, showing that genomic mosaicism was altered in the Alzheimer’s brain. Interestingly, these changes were not found everywhere, but were greatest in a part of the brain involved with complex thought.
Next, the researchers used a technique called single-cell qPCR to determine the numbers of APP copies in 154 individual neurons from Alzheimer’s and normal brains. They also tested the neurons using a technique called FISH as an independent method to assess APP copies using fluorescent probes. The researchers then quantified the copies of APP using both techniques.
The tests showed that neurons from patients with sporadic Alzheimer’s disease were four times as likely to contain more than the normal two copies of APP, with some Alzheimer’s neurons containing up to 12 copies of APP, a phenomenon never seen in the controls.
“A lot of people are still not aware of genomic mosaicism in the brain, so to be able to connect it with a disease is really interesting,” said Gwen Kaeser, a graduate student studying in Chun’s lab and co-first author of the study with former graduate student Diane Bushman.
A Clue to Other Brain Diseases
While genetic tests on blood samples can reveal if a person is prone to developing an inherited, familial form of Alzheimer’s, most people who develop Alzheimer’s do not test positive. The new study suggests that such genetic signatures might be lacking in the blood of the majority of patients because the genomic signatures of sporadic Alzheimer’s disease occur within individual brain cells.
Indeed, a majority of major brain diseases are also sporadic. For example, amyotrophic lateral sclerosis (ALS) can be linked to a gene in one to two percent of cases, but the rest are sporadic, having no known cause. Chun believes genomic mosaicism could possibly have a role in other brain diseases.
Future studies in the Chun lab will investigate the relationship between mosaicism and disease, the causes of mosaicism and potential new disease drug targets present in the millions of extra base-pairs found in single, Alzheimer’s disease neurons.
In addition to Chun, Kaeser and Bushman, other authors of the study, “Genomic mosaicism with increased amyloid precursor protein (APP) gene copy number in single neurons from sporadic Alzheimer's disease brains,” were Jurgen W. Westra of TSRI, now at Genedata Inc.; Stevens K. Rehen of TSRI, now at the Federal University of Brazil; and Richard R. Rivera, Benjamin Siddoway and Yun C. Yung, all of TSRI. For more information, see http://elifesciences.org/content/4/e05116.
This study received support from the National Institutes of Health (MH076145 and T32 DA07315, T32 AG 000216) and the Shaffer Family Foundation.
About the Scripps Research Institute
The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs about 3,000 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including three Nobel laureates—work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.